Nuwellis, Inc.

Snapshot

Nuwellis is a tiny medical-device maker whose FY 2025 revenue of $8.3M fell 5.4% YoY, with a $17.5M net loss, more than double revenue.

What's Happening Right Now

• Tue 27th Oct '26 · Clinical data: Nuwellis announced acceptance of its ULTRA-Peds Registry study (91 pediatric patients, 87% survival) in Pediatric Nephrology, backing a proposed FDA label expansion of Aquadex down to patients weighing 5 kg.
• Fri 23rd Oct '26 · Reverse split: Nuwellis filed an 8-K for a 1-for-9 reverse stock split effective October 26, 2026, its second reverse split in four months, typically done to regain Nasdaq compliance.
• Wed 26th Aug '26 · Dilutive offering: Nuwellis closed a $3.4M registered direct offering and private placement in August 2026 at $2.59/share (a steep discount to the prior close) and registered the resale of warrant shares that could lift shares outstanding by roughly 37%.
• Wed 26th Aug '26 · Registration: Registered 150K shares for sale on Form S-3.
• Tue 25th Aug '26 · Distribution deal: Nuwellis signed a co-promotion and distribution agreement with Atrility Medical for the AtriAmp device, a pilot that could lead to Nuwellis becoming its exclusive U.S. distributor.
• Thu 13th Aug '26 · Going concern: Nuwellis' Q2 10-Q disclosed substantial doubt about continuing as a going concern, a $325.7M accumulated deficit, a stockholders' deficit below Nasdaq's minimum equity requirement, and two material weaknesses in internal controls, despite a narrower $4.8M net loss and 76.1% gross margin.
• Mon 3rd Aug '26 · Offering: Raised $3.40M in gross proceeds through a registered direct offering, with warrants over 150K shares.
• Thu 30th Jul '26 · Offering: Raised $3.30M in gross proceeds through an offering.